Bortezomib for immune thrombocytopenia that came back or did not respond to treatment
Tests bortezomib in adults whose immune thrombocytopenia returned or resisted earlier treatment.
Key facts
- Who runs it
- Seoul National University Hospital
- Where
- South Korea3 sites in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- The Investigate Efficacy and Safety Evaluation of Bortezomib in Patients With Relapsed/Refractory Immune Thrombocytopenia
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 29 people, planned
- Started
- 7 Jul 2023
- Expected to end
- 31 Dec 2028
- Type of study
- Interventional
- Treatments tested
- Bortezomib
- Record updated
- 2 February 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with immune thrombocytopenia (ITP, a low platelet count caused by the immune system) that came back or did not respond to earlier treatments. They will receive bortezomib.
- Age
- 19 years and older
- Sex
- Men and women
- Disease stage
- Primary or secondary immune thrombocytopenia that relapsed or did not respond to treatment. Platelets must be below 30 x 109/L and treatment must be needed.
- Earlier treatment
- Relapsed or no response after corticosteroids (prednisolone cumulative dose 5.6mg/kg or more, or dexamethasone cumulative dose 80mg or more), unless corticosteroids cannot be used. Also relapsed or no response after at least 2 other kinds of treatment, such as splenectomy, eltrombopag or romiplostim, rituximab, azathioprine, cyclosporine or MMF, vincristine or cyclophosphamide, danazol, dapsone or alemtuzumab.
- Biomarker or test result
- A bone marrow test within the past 5 years must show the low platelets are not caused by the bone marrow. Also at least one of these: a full platelet response (plt >100k) to immunoglobulin therapy, proven anti-platelet antibody, or proven autoimmune markers (such as Helicobacter IgG, ANA, ACA, NSI). Women who can become pregnant need a negative pregnancy test within 28 days before starting.
Main reasons for not taking part
- Pregnant or breastfeeding women
- Allergy to bortezomib, or Grade 2 or higher nerve damage (peripheral neuropathy) needing drugs
- Severe or uncontrolled active infection, or HBV, HCV or HIV unless stable on antiviral treatment
- Currently having chemotherapy or in another clinical trial
- Poor organ function: total bilirubin > 3 x ULN, creatinine > 1.5 x ULN, or AST & ALT > 3 x ULN
The registry criteria, word for word
Show all 22 criteriaShow less
Who can take part
- Men and women 19 years of age and older
- Patients diagnosed with immune thrombocytopenia (primary or secondary)
- (Patients with at least one of B, C, or D meeting A below.) A.A person who has been confirmed not to be due to a cause of decreased platelet production in the bone marrow in the results of bone marrow examination within the past 5 years. (Bone marrow examination is required if there is no bone marrow examination result within the last 5 years.) B.After being diagnosed with ITP, there has been a case of complete platelet response with plt >100k in immunoglobulin therapy; C.Patients suspected of having primary immune thrombocytopenia with proven anti-platelet antibody., D.Helicobacter IgG, antinuclear antibody (ANA), anticardiolipin antibody (ACA), nonspecific inhibitor (NSI), etc. have been proven, and secondary immune thrombocytopenia caused by autoimmune disease is suspected
- platelets <30 x 109/L
- Patients in need of clinical treatment
- Patients who have relapsed or refractory after receiving treatment with corticosteroids (prednisolone cumulative dose 5.6mg/kg (0.8mg/kg 1 week) or more or dexamethasone cumulative dose 80mg (20mg 4 days) or more)., However, there are exceptions when corticosteroids are contraindicated
- Patients who have been relapsed or refractory after receiving at least 2 treatments with a mechanism other than corticosteroids
- Patients who underwent two different treatments from among the treatment methods below; Splenectomy; eltrombopag or romiplostim; Rituximab treatment; Azathioprine; cyclosporine or mycophenolate mofetil(MMF); vincristine or cyclophosphamide; danazol; dapsone; Alemtuzumab
- Female patients of childbearing potential should have a negative urine or serum pregnancy test within 28 days before starting administration of the test drug
- Patients who voluntarily or legal guardians have given written consent to participate in this clinical trial
Who cannot take part
- Patients with Grade 2 or higher peripheral neuropathy requiring drug treatment
- Patients currently undergoing chemotherapy
- Patients allergic to bortezomib
- Patients with severe or uncontrolled active infection
- HBV, HCV carrier or HIV patient. (However, if the patient is being stably maintained with antiviral treatment, and the expert opinion determines that it is possible to participate in the clinical trial along with antiviral treatment and prevention, participation is possible.)
- Patients whose bone marrow did not recover after cancer treatment, or whose cause other than immune destruction was confirmed by bone marrow examination, such as thrombocytopenia due to intramedullary abnormalities. However, if the presence of anti-platelet antibodies is proven and thrombocytopenia due to immune destruction is strongly suspected clinically, registration is possible even if there are other causes of thrombocytopenia.)
- Patients with inadequate organ function; total bilirubin > 3 x ULN; creatinine > 1.5 x ULN; liver function test AST(SGOT) \& ALT(SGPT) > 3 x ULN
- Patients who may become pregnant. However, women of childbearing age(If postmenopausal women are not of childbearing age, they must have been menstruating for at least 12 months.) who have not undergone sterilization can participate in the clinical trial only if the pregnancy test is negative. And, effective contraception must be maintained throughout the entire trial period
- pregnant, lactating women
- Patients with significant immunoglobulin degradation in the immunoglobulin profile
- Patients currently participating in other clinical trials
- Patients who are not considered suitable for participation in clinical trials in the opinion of the researcher
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
to investigate efficacy and safety evaluation of bortezomib in patients with relapsed/refractory immune thrombocytopenia
The group in the trial
- TreatmentTreatment being tested
Bortezomib is administered at 1.3mg/m2 iv or sc on each Cycly Day1, Days4, and Days8. Bortezomib is administered every 3 weeks for a total of 3 cycles. Thereafter, follow-up is scheduled for 12 months.
Treatment: Bortezomib
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 2 Study to Investigate Efficacy and Safety Evaluation of Bortezomib in Patients With Relapsed/Refractory Immune Thrombocytopenia
- Plain-language title
- Bortezomib for immune thrombocytopenia that came back or did not respond to treatmentGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 2 February 2026